DOCSLIB.ORG

Cphi & P-MEC China Exhibition List展商名单version版本20180308

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cphi & P-MEC China Exhibition List展商名单version版本20180308 CPhI & P-MEC China Exhibition List展商名单 Version版本 20180308 Booth/ Company Name/公司中英文名 Product/产品 展位号 Carbosynth Ltd E1A01 IPTG,EDAC HCl,2-脱氧-D-核糖IPTG,EDAC HCl,2-deoxy-D-ribose Analytical standards,Natural products,Amino acids and peptides,Steroids,API’s, impurities, and metabolites,Stable isotope labelled analogues,Building blocks,Chiral molecules,Carbohydrates and oligosaccharides,Nucleic acid derivatives,Enzyme Toronto Research Chemicals Inc E1A08 activators and inhibitors,Sulfhydryl active agents,Fluorescent reagents,Spin labels,Nicotine derivatives and metabolites,Neurochemicals,Environmental standards,mutagens, and metabolites,Phthalates,Retinoids,Vitamin D derivatives,Drugs of abuse for forensic testing,Phosphates SiliaMetS,SiliaCat,SiliaFlash,SiliaBond,Metal Scavenger,Catalyst,silica SiliCycle Inc. E1A10 gel,chromatographic phases SA TOURNAIRE E1A11 铝,包装,瓶,原料药Aluminum,Bottle,Packaging,API 紫杉醇,多西他赛,秋水仙碱,利血平,硫秋水仙碱苷,欧洲越橘,葡萄籽,银杏叶,姜黄,橄榄果,绿茶,水飞 蓟,乳香,锯叶棕,积雪草Paclitaxel,Docetaxel, Indena SpA E1A17 Colchicine,Reserpine,Thiocolchicoside,Bilberry,Grape Seed,Ginkgo Biloba,Curcumin,Olive,Green Tea, Silymarin, Boswellia,Saw Palmetto,Centella Asiatica Chempro Pharma PVT LTD E1A19 Trifarma E1A21 LLC Velpharma E1A25 Anuh Pharma E1A31 Moehs Iberica S.L E1A32 BROMOBENZENE,N PROPYL BROMIDE,SODIUM BROMIDE,ETHYL Chemclone Industries E1A51 BROMIDEBROMOBENZENE,NPROPYL BROMIDE,SODIUM BROMIDE,ETHYL BROMIDE Chemwerth Inc. E1B01 Hetero Labs Limited E1B09 Tacrolimus,Mycophenolate Mofetil,Mycophenolate Sodium,Cyclosporine,Sirolimus,Pimecrolimus,Temsirolimus,Everolimus,Romidepsin,Mitomyci Concord Biotech Limited E1B10 n,Dactinomycin,Teicoplanin,Fidaxomicin,Mupirocin,Mupirocin Calcium,Anidulafungin,Micafungin Sodium,Milbemycin Oxime,Daptomycin,Retapamulin,Doxorubicin,Epirubicin,Bleomycin,Dalbavancin Abiraterone acetate,Anastrozole,Apixaban,Apremilast,Atazanavir sulfate,Azacitidine,Benazepril hydrochloride,Bimatoprost,Bivalirudin,Bortezomib,Capecitabine,Celecoxib,Cladribine,Da ntrolene sodium,Decitabine,Desmopressin acetate,Docetaxel anhydrous,Docetaxel ScinoPharm Taiwan Ltd E1B11 trihydrate,Entecavir,Enzalutamide,Everolimus,Exemestane,Flumazenil,Fluticasone propionate,Fulvestrant,Galantamine,Galantamine hydrobromide,Gefitinib,Gemcitabine hydrochloride,Granisetron hydrochloride,Ibrutinib,Irinotecan hydrochloride,Lapatinib ditosylate,Letrozole,Octreotide acetate,Omeprazole,Ondansetron Leuprolide acetate depot injection,Cross-linked hyaluronic acid filler,Propofol injection,Daptomycin,Teicoplanin,Alprostadil injection,Octreotide LAR Dongkook Pharmaceutical Co., Ltd. E1B19 injection,Liposomal amphotericin B injection,DOTA,Iopamidol,Gadopentetate meglumine,Entecavir depot injection,Teriparatide acetate injection,Donepezil depot injection Shenzhen Salubris Pharmaceuticals Co., Ltd E1B22 吡混,呋辛,西丁Cefepime ,Cefuroxime,Cefoxitin GfM mbH E1B25 Leawell International Ltd E1B28 IDL 地高辛,丁溴东莨菪碱,甲基硫酸新斯的明,5-氟尿嘧啶Digoxin,Hyoscine DCS Pharma AG E1B31 Butylbromide,Neostigmine Methylsulfate,5-Fluorouracil Agno Pharma E1B32 Newchem Spa E1B35 APEX HEALTHCARE LIMITED E1B51 AMRI E1C21 Active Pharmaceutical Ingredients,Intermediates,Excipients and Drug Formulation Aarti Drugs Limited E1C25 Espee Group Innovators E1C31 RLDs Ruland Chemical Co., Ltd. E1C32 原料药,中间体,生化药剂,营养补充剂APIs,Intermediates,Biochemicals,Nutritional Supplements Merck Chemicals (Shanghai) Co., Ltd. E1C51 Parteck®SRP 80,Parteck®MXP,Parteck®Delta 甘露醇 Mediking Pharmaceutical Group Ltd E1C57 托品醇,去甲托品醇,托品酮,托品酸tropanes series,tropine,nortropine The United Laboratories International Holdings E1D01 Ltd./珠海联邦制药股份有限公司 FMC Corporation E1D02 对氨基三氟甲氧基苯,2,6-二溴-4-三氟甲氧基苯胺,对三氟甲氧基苯酚,4-三氟甲氧基苯基异氰酸酯,间 三氟甲基苯甲酸甲酯,2-氯-5-氨基三氟甲苯 ,4-三氟甲基苯甲醛,2,6-二氟-4-溴三氟甲氧基苯,2-溴-4- 甲基苯酚,4,4\'\'-二溴-p-三联苯,全氟丁醇,全氟丁酸,全氟丁基磺酰氟,五氟苯酚,茚满,氟化氢三乙 胺,2-氟丙二酸二乙酯,5-三氟甲基尿嘧啶4-Trifluoromethoxy aniline,2,6-Dibromo-4- Kingchem (Liaoning) Chemical Co., Ltd E1D10 trifluoromethoxyaniline,4-Trifluoromethoxy phenol,4-(Trifluoromethoxy) phenyl isocyanate,Methyl 3-(trifluoromethyl) benzoate,5-Amino-2-chlorobenzotrifluoride,4- Trifluoromethyl benzaldehyde,2,6-Difluoro-4-bromo(trifluoromethoxy)benzene,2-Bromo-4- methylphenol,4,4’’-dibromo-p-terphenyl,2,2,3,3,4,4,4- Ovolecithin(DS-PL95E),Soy Lecithin(DS-Soya series),Ceramide(DS-Cera series),Egg Doosan Corporation E1D22 Lecithin(DS-PL series) Sunasia Co., Ltd. E1D25 Dacarbazine Bolon Pharmachem Co., Ltd. E1D26 cyclen,fosinopril inter,trimebutine,Fulvestrant,2-Methoxyethylamine,Glatiramer,cyclam Savior Lifetec Corporation E1D27 美洛培南,厄他培南,柳菩林,特立帕肽Meropenem,Ertapenem,Leuprolide,Teriparatide Alchem International Pvt Ltd E1D31 Polish Investment and Trade Agency E1D57 Albendazole,Alfuzosin HCl,Ambroxol HCl,Amoxicillin Trihydrate,Analgin ,Metamizol Sodium,Atorvastatine,Atorvastatine Calcium,Azelaic Acid,Bacitracin Zinc,Bisoprolol Hemifumarate,Budesonide,Caffeine,Captopril,Carbamazepine,Chlorzoxazone,Ciproflox acin Base,Ciprofloxacin HCl,Cisplatin,Clarithromycin,Clopidogrel Form I,Colistin Fischer Chemicals AG E1E01 Sulphate,Dehydrocholic Acid,Dextromethorphan Hydrobromide,Diacerein,Diclofenac Sodium,Dihydrocodeine Bitartrate,Diltiazem HCl,Doxycycline Hyclate,Enrofloxacin,Erythromycin Base,Erythromycin Stearate,Estramustine Sodium Phosphate,Ethion,Famotidine,Fentanyl Citrate,Florfenicol,Fluticasone Acetate,Fluticasone 三氮脒,克洛索隆,硝碘酚腈,布帕伐醌,硝唑尼特Diminazene Diaceturate,Clorsulon,Buparvaquone,Toldimfos Sodium,Triclabendazole,Praziquentel,Flunixin Meglumine,Imidocarb NGL Fine Chem Limited E1E24 Dipropioinate,Nitroxynil,Parvaquone,Butaphosphan,Bithionol Sulfoxide,S- Methoprene,Nitazoxanide,Ranolazine,Febuxostat,Atovovquone,Homidium Tabs,Diminazene Sachets ECCO Roller/常州艾柯轧辊有限公司 E1E25 Butylscopolamine,Vincamine,Vinpocetine,5-HTP,Bilberry,Ginkgo,MedCan,HMRlignan,Red Linnea SA E1E26 clover,NioSkin,SylTech 米索前列醇-羥丙基甲基纖維素1%,前列地爾,依前列醇鈉,利马前列素阿法环糊精,鲁比前列酮,拉坦前 列素,貝美前列素,曲伏前列素,曲前列尼爾,非洛地平,甲磺酸雷西吉蘭,硼替佐米,吉非替尼,芬戈莫德, Everlight Chemical Industrial Corporation E1E27 納呋拉啡,氯前列醇鈉Misoprostol-HPMC,Alprostadil,Epoprostenol Sodium,Limaprost alfadex,Lubiprostone,Latanoprost,Bimatoprost,Travoprost,Treprostinil,Felodipine,Rasagilin e Mesylate,Bortezomib,Gefitinib,Fingolimod HCL,Nalfurafine HCL,Cloprostenol Sodium HARMAN FINOCHEM E1E28 Atorvastatin,Pregabalin,Sitagliptin,Olmesartan,Etodolac,Gliclazide,Bosentan,Voglibose,Li maprost,Bimaprost,Beraprost,Lubiprostone,Treprostinil,Dronedarone,Telmisartan,Furosemi Zhechem Co Ltd E1F01 de,Duloxetine,Gabapentin,Abiraterone,Efavirenz,Posaconazole,Efinaconazole,Tenofovir, Montelucast,Phenibut,Propranolol,Travoprost,Dinoprostone Midas Pharma GmbH Shanghai Representativ E1F03 Pharmaceutical Services Supriya Lifescience Ltd E1F10 Pheniramine Maleate,Brompheniramine Maleate,Salbutamol Sulphate,Cetirizine Di HCl KOA Shoji Co Ltd E1F22 APIs,Intermediates 高纯度活化PEG,高纯度吐温80,高纯度磷脂Activated- NOF Corporation E1F24 PEG,Polysorbate80,Phospholipid,Polysorbate20 Heraeus Materials Technology Shanghai Ltd./上 E1F26 海贺利氏工业技术材料有限公司 扑热息痛,阿司匹林,水杨酸甲酯,水杨酸,水杨酸辛酯,胡莫柳酯,烯丙醇,对氨基苯酚,碳酸氢钠,异丙醇, 苯乙酮Paracetamol,Aspirin,Methyl Salicylate,Salicylic Acid,Octyl Novacyl Asia Pacific Ltd E1F28 Salicylate,Homosalate,Allyl Alcohol,Para amino phenol,Sodium Bicarbonate,Isopropanol,Acetophenone PharmSol Europe Limited E1F32 COMPLIANCE,MARKET ACCESS & SUPPLY CHAIN,PROJECT MANAGEMENT,GDP Bachem AG E1F35 Atosiban,Desmopressin,Goserelin,Triptorelin acetate Louston International Inc. E1F51 氯前列醇钠cloprostenol sodium High Science Co Ltd E1F55 Azacitidine for injection,Pemetrexed disodium for injection,Bortezomib for injection,Voriconazole for injection ,Alprostadil for injection,Azacitidine,Bortezomib,Pemetrexed disodium Chemsphere Technology Inc. E1F57a ,Paclitaxel,Docetaxel,Sulfamethoxazole sodium,Mesulphen,Astaxanthin,Chitosan Oligosaccharide Lactate,Alfa-Calcidol,Calcifediol,Ergocalciferol,γ-PGA,CMO/CRO Service,Quality Consistency Evaluation for Generic Drugs PharmaCore Biotech Co., Ltd. E1F57b Rockwood Lithium GmbH E1G51 锂化学品,有机金属化合物,丁基锂Lithium,Organometallics,Butyllithium Sigachi Industries Pvt Ltd. E1G53 Thiocolchicoside,Colchicine,Reserpine,Yohimbine, Deacetyl Baccatine III (10-DAB III),Paclitaxel,Docetaxel,Raubasine,Garcenia Combogia,Gymnema Sarv Bio Labs Pvt Ltd E1G57 SylvestreThiocolchicoside,Colchicine,Reserpine,Yohimbine, Deacetyl Baccatine III (10- DAB III),Paclitaxel,Docetaxel,Raubasine,Garcenia Combogia,Gymnema Sylvestre 抗病毒类、抗肿瘤类、抗感染类和甾体类中间体、原料药和药物制剂及医药合约研发和加工服务 Shanghai Desano Pharmaceuticals Co., Ltd./上 APIs and Finished products of ARV, Oncology, Anti-infection and Hormone drugs and E1H01 海创诺医药集团有限公司 pharmaceutical CRO & CDMO service APIs and Finished products of ARV, Oncology, Anti-infection and Hormone drugs and pharmaceutical CRO & CDMO service 培他米松、地塞米松、泼尼松、泼尼松龙、甲泼尼龙、醋酸氢化可的松、螺内酯、氨基酸、GCLE 、7AVCA、头孢地尼、核黄素磷酸钠、甲睾酮、阿替洛尔、尼莫地平、阿加曲班、尼美舒利、阿 德福韦酯、注射用氢化可的松、注射用马来酸阿奇霉素、肝素钠注射液、注射用尿激酶、黄芪皂苷 Tianjin Tianfa Pharmaceuticals Imp. & Exp. Corp. I、II、III、番泻叶提取物、甜菊糖苷、萝卜硫素。Betamethasone Base, Dexamethasone Base, E1H16 /天津市医药集团有限公司 Prednisone, Prednisolone, Methylprednisolone, Hydrocortisone Acetate, Spironolactone, Amino Acid, Budesonide, Fluocinolone Acetonide, Fluocinonide, Triamcinolone Base, Triamcinolone Acetonide, Halcinonide, Hydrocortisone Butyrate, GCLE, Cefidinir, 头孢克肟,头孢地尼,氧氟沙星,左氧氟沙星,盐酸环丙沙星,盐酸克林霉素,拉索拉唑,奥美沙坦,替米沙Biboflavin-5-Phosphate Sodium, Methyltestosterone, Atenolol, Nimodipine, Argatroban, 坦,UDCA,尼扎替丁,伊贝沙坦, 氟比洛芬, 洛索洛芬钠, 美索巴莫, 瑞巴派特, 盐酸金刚烷胺, 盐酸安非 他酮, 盐酸多奈哌齐, 加巴贲丁, 氟苯尼考, 碘海醇, 氯霉素, 中间体, 化工品Cefixime, Cefdinir, Zhejiang Hengdian Apeloa Imp. &Exp. Co., Ltd./ Ofloxacin, Levofloxacin, Ciprofloxacin HCl, Clindamycin Hydrochloride, Lansoprazole, E1H20 浙江横店普洛进出口有限公司 Olmesartan, Telmisartan,
Load more

Recommended publications
  • Pharmacological Investigations of Natural Β2-Adrenoceptors Agonists
    University of Szeged Faculty of Pharmacy Department of Pharmacodynamics and Biopharmacy Pharmacological investigations of natural β 2-adrenoceptors agonists on rat uterus in vitro and in silico studies Ph.D. Thesis By Aimun Abdelgaffar Elhassan Ahmed Pharmacist Supervisor Prof. Dr. George Falkay, Ph.D., D.Sc. Szeged, Hungary 2012 ~~xX ♥@ DEDICATION @♥Xx~~ @@@@@ I dedicate this work To my lovely parents, To my wife and kids To my brothers and sisters To all whom I love With my deepest love and Respect . ~~xX ♥@ Aimun @♥Xx~~ Publications list Publications related to the PhD thesis 1. Aimun Abdelgaffar Elhassan Ahmed , Robert Gaspar, Arpad Marki, Andrea Vasas, Mahmoud Mudawi Eltahir Mudawi, Judit Hohmann and George Falkay. Uterus-Relaxing Study of a Sudanese Herb (El-Hazha). American J. of Biochemistry and Biotechnology 6 (3): (2010) 231-238, ……... IF: 1.493 2. Aimun AE. Ahmed , Arpad Marki, Robert Gaspar, Andrea Vasas, Mahmoud M.E. Mudawi, Balázs Jójárt, Judit Verli, Judit Hohmann, and George Falkay. β2-Adrenergic activity of 6-methoxykaempferol-3-O-glucoside on rat uterus: in vitro and in silico studies. European Journal of Pharmacology 667 (2011) 348–354……………………..... IF: 2.737 3. Aimun AE. Ahmed , Arpad Marki, Robert Gaspar, Andrea Vasas, Mahmoud M.E. Mudawi, Balázs Jójárt, Renáta Minorics, Judit Hohmann, and George Falkay. In vitro and in silico pharmacological investigations of a natural alkaloid. Medicinal Chemistry Research, DOI:10.1007/s00044-011-9946-0,………….... IF: 1.058 Other publication Ahmed A EE , Eltyeb I B, Mohamed A H. Pharmacological activities of Mangifera indica Fruit Seed Methanolic Extract. Omdurman Journal of Pharmaceutical Sciences (2006), 1(2): 216-231, (Local Sudanese).
    [Show full text]
  • Galeterone for the Treatment of Castration- Resistant Prostate Cancer Bruce Montgomery1, Mario A
    Published OnlineFirst November 2, 2015; DOI: 10.1158/1078-0432.CCR-15-1432 Cancer Therapy: Clinical Clinical Cancer Research Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration- Resistant Prostate Cancer Bruce Montgomery1, Mario A. Eisenberger2, Matthew B. Rettig3, Franklin Chu4, Roberto Pili5, Joseph J. Stephenson6, Nicholas J. Vogelzang7, Alan J. Koletsky8, Luke T. Nordquist9, William J. Edenfield10, Khalid Mamlouk11, Karen J. Ferrante11, and Mary-Ellen Taplin12 Abstract Purpose: Galeterone is a selective, multitargeted agent that Results: In ARMOR1, across all doses, 49.0% (24/49) achieved a inhibits CYP17, antagonizes the androgen receptor (AR), and 30% decline in prostate-specific antigen (PSA; PSA30) and reduces AR expression in prostate cancer cells by causing an 22.4% (11/49) demonstrated a 50% PSA decline (PSA50). In increase in AR protein degradation. These open-label phase I ARMOR2 part 1, across all doses, PSA30 was 64.0% (16/25) and and II studies [Androgen Receptor Modulation Optimized PSA50 was 48.0% (12/25). In the 2,550-mg dose cohort, PSA30 for Response-1 (ARMOR1) and ARMOR2 part 1] evaluated was 72.7% (8/11) and PSA50 was 54.5% (6/11). Galeterone was the efficacy and safety of galeterone in patients with treat- well tolerated; the most common adverse events were fatigue, ment-naive nonmetastatic or metastatic castration-resistant increased liver enzymes, gastrointestinal events, and pruritus. Most prostate cancer (CRPC) and established a dose for further were mild or moderate in severity and required no action and there study. were no apparent mineralocorticoid excess (AME) events.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Mechanisms of Toxic Action of the Flavonoid Quercetin and Its Phase II Metabolites
    Mechanisms of toxic action of the flavonoid quercetin and its phase II metabolites Hester van der Woude Promotor: Prof. Dr. Ir. I.M.C.M. Rietjens Hoogleraar in de Toxicologie Wageningen Universiteit Co-promotor: Dr. G.M. Alink Universitair Hoofddocent, Sectie Toxicologie Wageningen Universiteit. Promotiecommissie: Prof. Dr. A. Bast Universiteit Maastricht Dr. Ir. P.C.H. Hollman RIKILT Instituut voor Voedselveiligheid, Wageningen Prof. Dr. Ir. F.J. Kok Wageningen Universiteit Prof. Dr. T. Walle Medical University of South Carolina, Charleston, SC, USA Dit onderzoek is uitgevoerd binnen de onderzoekschool VLAG Mechanisms of toxic action of the flavonoid quercetin and its phase II metabolites Hester van der Woude Proefschrift ter verkrijging van de graad van doctor op gezag van de rector magnificus van Wageningen Universiteit, Prof. Dr. M.J. Kropff, in het openbaar te verdedigen op vrijdag 7 april 2006 des namiddags te half twee in de Aula Title Mechanisms of toxic action of the flavonoid quercetin and its phase II metabolites Author Hester van der Woude Thesis Wageningen University, Wageningen, the Netherlands (2006) with abstract, with references, with summary in Dutch. ISBN 90-8504-349-2 Abstract During and after absorption in the intestine, quercetin is extensively metabolised by the phase II biotransformation system. Because the biological activity of flavonoids is dependent on the number and position of free hydroxyl groups, a first objective of this thesis was to investigate the consequences of phase II metabolism of quercetin for its biological activity. For this purpose, a set of analysis methods comprising HPLC-DAD, LC-MS and 1H NMR proved to be a useful tool in the identification of the phase II metabolite pattern of quercetin in various biological systems.
    [Show full text]
  • Download Product Insert (PDF)
    Product Information Galeterone Item No. 17586 N CAS Registry No.: 851983-85-2 Formal Name: 17-(1H-benzimidazol-1-yl)-androsta- 5,16-dien-3β-ol N Synonym: TOK-001 MF: C26H32N2O FW: 388.6 H Purity: ≥98% H H Stability: ≥2 years at -20°C Supplied as: A crystalline solid HO Laboratory Procedures For long term storage, we suggest that galeterone be stored as supplied at -20°C. It should be stable for at least two years. Galeterone is supplied as a crystalline solid. A stock solution may be made by dissolving the galeterone in the solvent of choice. Galeterone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of galeterone in ethanol and DMSO is approximately 20 mg/ml and approximately 30 mg/ml in DMF. Galeterone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, galeterone should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Galeterone has a solubility of approximately 0.2 mg/ml in a 1:3 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. The cytochrome P450 (CYP) isoform CYP17 is also known as steroid 17α-hydroxylase/17,20 lyase because it catalyzes both 17α-hydroxylase and 17,20 lyase reactions in the synthesis of steroids, including androgens, estrogens, glucocorticoids, 1 and mineralocorticoids. Galeterone is a CYP17 inhibitor (IC50 = 300 nM) that has been shown to competitively block synthetic androgen binding (EC50 = 845 nM) and to antagonize the androgen receptor in transcriptional activation 2 assays.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Natuurlijke Bèta-2-Agonisten in Sportsupplementen
    Natuurlijke bèta-2-agonisten in sportsupplementen FATIMA DEN OUDEN, WILLEM KOERT | In de gereguleerde sport is het gebruik van bèta-2-agonisten slechts onder strikte voorwaar- den toegestaan. Bèta-2-agonisten kunnen de zuurstofopname en spiermassa van atleten vergroten en hun vetmassa verminderen. Hoewel bèta-2-agonisten officieel alleen op recept verkrijgbaar zijn, zijn er aanwijzingen dat de sportsup- plementenindustrie natuurlijke stoffen met een bèta-2-adrenergene werking is gaan toepassen in bepaalde producten. Dit artikel vat samen om welke stoffen het gaat, en wat er in de wetenschappelijke literatuur over hun werking bekend is. Volgens studies gebruikt veertig tot tachtig de stof de pompfunctie van het hart [6] en natuurlijke stoffen die volgens studies de procent van de topsporters en fitnessfana- laat het de concentratie vrije vetzuren in bèta-2-adrenoceptor stimuleren. Supple- ten supplementen die sportprestaties zou- het bloed stijgen en het energieverbruik mentenproducenten combineren deze den moeten verbeteren, en veel van deze toenemen [7]. Voeg daar nog aan toe dat stoffen vaak met cafeïne [12], een milde sti- producten bevatten plantenextracten. In higenamine volgens in vitro-studies de mulerende verbinding die de biologische dit segment is de scheidslijn tussen food luchtwegen kan verwijden [8], en het is dui- effecten van bèta-2-agonisten versterkt[13] . en pharma vervaagd, onder meer doordat delijk waarom het misschien een interes- Een van deze natuurlijke stoffen staat al op sommige supplementen natuurlijke stof- sante stof voor sporters is. Maar uit de stu- de dopinglijst van de WADA. Dat is octop- fen bevatten in zulke hoge concentraties dies wordt ook duidelijk dat higenamine amine, een stof die onder meer in bittere dat het predicaat ‘natuurlijk’ discutabel bijwerkingen kan hebben, zoals hartklop- sinaasappel (Citrus x aurantium L.) voorkomt is geworden.
    [Show full text]
  • Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope
    cancers Review Therapies Targeted to Androgen Receptor Signaling Axis in Prostate Cancer: Progress, Challenges, and Hope Sirin Saranyutanon 1,2, Sanjeev Kumar Srivastava 1,2,*, Sachin Pai 3, Seema Singh 1,2,4 and Ajay Pratap Singh 1,2,4,* 1 Department of Pathology, College of Medicine, University of South Alabama, Mobile, AL 36617, USA; [email protected] (S.S.); [email protected] (S.S.) 2 Department of Oncologic Sciences, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA 3 Department of Medical Oncology, Mitchell Cancer Institute, University of South Alabama, Mobile, AL 36604, USA; [email protected] 4 Department of Biochemistry and Molecular Biology, College of Medicine, University of South Alabama, Mobile, AL 36688, USA * Correspondence: [email protected] (S.K.S.); [email protected] (A.P.S.); Tel.: +1-251-445-9874 (S.K.S.); +1-251-445-9843 (A.P.S.) Received: 4 November 2019; Accepted: 18 December 2019; Published: 23 December 2019 Abstract: Prostate cancer is the mostly commonly diagnosed non-cutaneous malignancy and the second leading cause of cancer-related death affecting men in the United States. Moreover, it disproportionately affects the men of African origin, who exhibit significantly greater incidence and mortality as compared to the men of European origin. Since androgens play an important role in the growth of normal prostate and prostate tumors, targeting of androgen signaling has remained a mainstay for the treatment of aggressive prostate cancer. Over the years, multiple approaches have been evaluated to effectively target the androgen signaling pathway that include direct targeting of the androgens, androgen receptor (AR), AR co-regulators or other alternate mechanisms that impact the outcome of androgen signaling.
    [Show full text]
  • Development of Combination Therapy for Prostate Cancer
    DEVELOPMENT OF COMBINATION THERAPY FOR PROSTATE CANCER A Dissertation Presented to the Faculty of the Weill Cornell Graduate School of Medical Sciences in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy by Alexander R. Root July 2017 © 2017 Weill Cornell Graduate School of Medical Sciences ALL RIGHTS RESERVED DEVELOPMENT OF COMBINATION THERAPY FOR PROSTATE CANCER Alexander R. Root, Ph.D. Cornell University 2017 There is an unmet need in prostate cancer for effective therapies to prevent the emergence of resistance. Combinations of small molecules targeting key pathways are a promising strategy. I investigated how populations of the early metastatic prostate cancer cell line LNCaP respond at the proteomic and pheno- typic levels to six clinically-relevant, one-drug treatments and their 15 pairs of two-drug combinations, administered simultaneously to treatment-naive cells. After 24 hours of drug addition for all 21 drug treatments I measured 52 total- proteins by selected-reaction monitoring mass-spectrometry based proteomics (SRM), 20 phospho-proteins, and 50 total-proteins by reverse-phase protein ar- rays (RPPA). I measured phenotypic effects on cell proliferation and apoptosis in all conditions using phase-contrast and fluorescence microscopy. Network analysis identified (phospho)-proteins with large responses to drug treatments that are druggable with FDA-approved drugs or have nearest-neighbors that are druggable. A total of ten drugs targeting these nearest responder (phospho)-proteins were tested in single, double, and triple combinations. I found that 7 out of 10 triple combinations co-targeting androgen receptor and PI3K pathways were no more effective than the two-drug combination at the doses tested: PRKC (en- zastaurin), MAPK (losmapimod), STAT3 (napabucasin), HDAC (panobinostat), SRC (saracatinib), casein kinase (silmitasertib), MAPK (ulixertinib).
    [Show full text]
  • ( 12 ) United States Patent
    US010314797B2 (12 ) United States Patent ( 10 ) Patent No. : US 10 , 314 ,797 B2 Narayanan et al. ( 45 ) Date of Patent : * Jun . 11, 2019 ( 54 ) SELECTIVE ANDROGEN RECEPTOR ( 56 ) References Cited DEGRADER (SARD ) LIGANDS AND METHODS OF USE THEREOF U . S . PATENT DOCUMENTS 5 ,480 ,656 A 1 / 1996 Okada et al . (71 ) Applicant: University of Tennessee Research 5 ,575 , 987 A 11/ 1996 Kamei et al . Foundation , Knoxville , TN (US ) 5 ,631 , 020 A 5 / 1997 Okada et al. 5 , 643 ,607 A 7 / 1997 Okada et al. 5 ,716 ,640 A 2 / 1998 Kamei et al. ( 72 ) Inventors : Ramesh Narayanan , Cordova , TN 5 , 814 ,342 A 9 / 1998 Okada et al . (US ) ; Duane D . Miller , Collierville , 6 ,036 , 976 A 3 / 2000 Takechi et al . TN (US ) ; Thamarai Ponnusamy , 7 , 118 , 552 B2 10 / 2006 Shaw et al . Memphis , TN (US ); Dong - Jin Hwang, 7 , 220 , 247 B25 / 2007 Shaw et al . 7 ,500 , 964 B23 / 2009 Shaw et al . Arlington , TN (US ) ; Yali He, 9 ,815 , 776 B2 * 11 / 2017 Narayanan . .. .. C07C 255 /60 Germantown , TN (US ) 9 , 834 , 507 B2 * 12 / 2017 Narayanan . .. .. .. C07C 255 /60 2005 /0101657 A1 5 /2005 Furuya et al . (73 ) Assignee : University of Tennessee Research 2007 /0265290 A1 11/ 2007 Dalton et al . 2010 /0227846 AL 9 /2010 Ito et al. Foundation , Knoxville , TN ( US ) 2014 / 0018433 A11 / 2014 Dalton et al . ( * ) Notice : Subject to any disclaimer , the term of this 2018 /0118663 A1 * 5 / 2018 Narayanan . C07C 237/ 20 patent is extended or adjusted under 35 FOREIGN PATENT DOCUMENTS U . S .
    [Show full text]
  • Inhibitory Effect of Acacetin, Apigenin, Chrysin and Pinocembrin on Human Cytochrome P450 3A4
    ORIGINAL SCIENTIFIC PAPER Croat. Chem. Acta 2020, 93(1), 33–39 Published online: August 03, 2020 DOI: 10.5562/cca3652 Inhibitory Effect of Acacetin, Apigenin, Chrysin and Pinocembrin on Human Cytochrome P450 3A4 Martin Kondža,1 Hrvoje Rimac,2,3 Željan Maleš,4 Petra Turčić,5 Ivan Ćavar,6 Mirza Bojić2,* 1 University of Mostar, Faculty of Pharmacy, Matice hrvatske bb, 88000 Mostar, Bosnia and Herzegovina 2 University of Zagreb, Faculty of Pharmacy and Biochemistry, Department of Medicinal Chemistry, A. Kovačića 1, 10000 Zagreb, Croatia 3 South Ural State University, Higher Medical and Biological School, Laboratory of Computational Modeling of Drugs, 454000 Chelyabinsk, Russian Federation 4 University of Zagreb, Faculty of Pharmacy and Biochemistry, Department of Pharmaceutical Botany, Schrottova 39, 10000 Zagreb, Croatia 5 University of Zagreb, Faculty of Pharmacy and Biochemistry, Department of Pharmacology, Domagojeva 2, 10000 Zagreb, Croatia 6 University of Mostar, Faculty of Medicine, Kralja Petra Krešimira IV bb, 88000 Mostar, Bosnia and Herzegovina * Corresponding author’s e-mail address: [email protected] RECEIVED: June 26, 2020 REVISED: July 28, 2020 ACCEPTED: July 30, 2020 Abstract: Cytochrome P450 3A4 is the most significant enzyme in metabolism of medications. Flavonoids are common secondary plant metabolites found in fruits and vegetables. Some flavonoids can interact with other drugs by inhibiting cytochrome P450 enzymes. Thus, the objective of this study was to determine inhibition kinetics of cytochrome P450 3A4 by flavonoids: acacetin, apigenin, chrysin and pinocembrin. For this purpose, testosterone was used as marker substrate, and generation of the 6β-hydroxy metabolite was monitored by high performance liquid chromatography coupled with diode array detector.
    [Show full text]
  • Cphi & P-MEC China Exhibition List展商名单version版本20180116
    CPhI & P-MEC China Exhibition List展商名单 Version版本 20180116 Booth/ Company Name/公司中英文名 Product/产品 展位号 Carbosynth Ltd E1A01 Toronto Research Chemicals Inc E1A08 SiliCycle Inc. E1A10 SA TOURNAIRE E1A11 Indena SpA E1A17 Trifarma E1A21 LLC Velpharma E1A25 Anuh Pharma E1A31 Chemclone Industries E1A51 Hetero Labs Limited E1B09 Concord Biotech Limited E1B10 ScinoPharm Taiwan Ltd E1B11 Dongkook Pharmaceutical Co., Ltd. E1B19 Shenzhen Salubris Pharmaceuticals Co., Ltd E1B22 GfM mbH E1B25 Leawell International Ltd E1B28 DCS Pharma AG E1B31 Agno Pharma E1B32 Newchem Spa E1B35 APEX HEALTHCARE LIMITED E1B51 AMRI E1C21 Aarti Drugs Limited E1C25 Espee Group Innovators E1C31 Ruland Chemical Co., Ltd. E1C32 Merck Chemicals (Shanghai) Co., Ltd. E1C51 Mediking Pharmaceutical Group Ltd E1C57 珠海联邦制药股份有限公司/The United E1D01 Laboratories International Holdings Ltd. FMC Corporation E1D02 Kingchem (Liaoning) Chemical Co., Ltd E1D10 Doosan Corporation E1D22 Sunasia Co., Ltd. E1D25 Bolon Pharmachem Co., Ltd. E1D26 Savior Lifetec Corporation E1D27 Alchem International Pvt Ltd E1D31 Polish Investment and Trade Agency E1D57 Fischer Chemicals AG E1E01 NGL Fine Chem Limited E1E24 常州艾柯轧辊有限公司/ECCO Roller E1E25 Linnea SA E1E26 Everlight Chemical Industrial Corporation E1E27 HARMAN FINOCHEM E1E28 Zhechem Co Ltd E1F01 Midas Pharma GmbH Shanghai Representativ E1F03 Supriya Lifescience Ltd E1F10 KOA Shoji Co Ltd E1F22 NOF Corporation E1F24 上海贺利氏工业技术材料有限公司/Heraeus E1F26 Materials Technology Shanghai Ltd. Novacyl Asia Pacific Ltd E1F28 PharmSol Europe Limited E1F32 Bachem AG E1F35 Louston International Inc. E1F51 High Science Co Ltd E1F55 Chemsphere Technology Inc. E1F57a PharmaCore Biotech Co., Ltd. E1F57b Rockwood Lithium GmbH E1G51 Sarv Bio Labs Pvt Ltd E1G57 抗病毒类、抗肿瘤类、抗感染类和甾体类中间体、原料药和药物制剂及医药合约研发和加工服务 上海创诺医药集团有限公司/Shanghai Desano APIs and Finished products of ARV, Oncology, Anti-infection and Hormone drugs and E1H01 Pharmaceuticals Co., Ltd.
    [Show full text]